Mumbai : The unaudited financial statements for Q4FY26 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.
Key Consolidated Financial Highlights:
| Particulars | Q4 FY26 | Q4 FY25 |
| Revenues (in Rs Cr) | 276.53 | 184.11 |
| EBITDA (in Rs Cr) | 97.62 | 67.58 |
| EBITDA Margin | 35.3% | 36.7% |
| PAT (in RsCr) | 74.23 | 50.37 |
| PAT Margin | 26.8% | 27.4% |
| Quarterly EPS (in Rs) | 9.22 | 6.29 |
Key Consolidated Financial Highlights:
| Particulars | FY26 | FY25 |
| Revenues (in Rs Cr) | 827.87 | 696.48 |
| EBITDA (in Rs Cr) | 294.05 | 260.79 |
| EBITDA Margin | 35.5% | 37.4% |
| PAT (in RsCr) | 209.12 | 187.96 |
| PAT Margin | 25.3% | 27.0% |
| EPS (in Rs) | 25.98 | 23.35 |
Key Highlights for Q4 FY26:
In Q4 FY26, Supriya Lifescience Ltd. witnessed a 50.2% year-over-year growth in Revenue to Rs 276.53 crore compared to Rs 184.11 crore in Q4 FY25.
EBITDA for Q4 FY26 stood at Rs 97.62 crore, with an EBITDA margin of 35.3%, as against Rs 67.58 crore in Q4 FY25 with a margin of 36.7%.
The Profit After Tax (PAT) for Q4 FY26 was Rs 74.23 crore, compared to Rs 50.37 crore in Q4FY25.
The PAT Margin stood at 26.8% in Q4 FY26 versus 27.4% in Q4 FY25.
Key Highlights for FY26:
Revenue from operations for FY26 grew by 18.9% YoY to Rs 827.87 crore compared to Rs 696.48 crore in FY25.
EBITDA for FY26 stood at Rs 294.05 crore as against Rs 260.79 crore in FY25, registering a growth of 12.8% YoY. EBITDA margin for FY26 stood at 35.5%.
PAT for FY26 increased by 11.3% YoY to Rs 209.12 crore compared to Rs 187.96 crore in FY25. The PAT Margin stood at 25.3% in FY26 versus 27.0% in FY25.
The anesthetic segment continued to be the primary growth driver during FY26, contributing 54% of total revenues compared to 49% in FY25, while the vitamins segment also witnessed improved traction with its contribution increasing to 12% from 11% during the same period. Europe remained the Company’s largest market, contributing 40% of FY26 revenues and 44% of Q4 FY26 revenues, followed by Asia at 33% for FY26 and 34% in Q4 FY26, while LATAM contributed 20% and 17%, respectively.
Export contribution remained strong at approximately 82% of FY26 revenues, supported by diversified customer relationships and continued penetration into regulated markets. During the year, the Company commercialised its Liquid Anesthetic product and witnessed encouraging traction in newly launched products across the cardiovascular and ADHD segments.
Capacity utilisation improved to 74% in FY26 from 70% in FY25, supported by the ramp-up of Module E at the Lote facility and continued operational efficiencies. The Company further strengthened its long-term manufacturing and expansion roadmap through strategic land acquisitions near its existing facilities and at Isambe, Patalganga. Additionally, the Ambernath formulation facility commissioned five finished dosage manufacturing lines and continues to progress on validation and dossier submission activities across multiple regulated markets.
Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, “The strong performance delivered during Q4 FY26 and across the full year reflects steady demand across our key therapeutic segments, healthy traction in regulated markets, and continued operational focus across the business. Improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the year. During FY26, we continued to strengthen our manufacturing and R&D infrastructure through capacity enhancement initiatives, strategic land acquisitions, and progress at our Ambernath formulation facility. The commercialisation of the Liquid Anesthetic product, advancement in our finished dosage capabilities, and continued focus on backward integration further strengthened the foundation of our business. With a diversified product portfolio, strong customer relationships across global markets, and ongoing investments in innovation and manufacturing capabilities, the Company remains well positioned to drive sustainable long-term growth.”
